Heart Beat: Osteoporosis drugs not linked to atrial fibrillation
Heart Beat
Osteoporosis drugs not linked to atrial fibrillation
Bone-strengthening drugs taken by millions of Americans to fight osteoporosis and other conditions aren't linked to the onset of the fast, irregular heart rhythm known as atrial fibrillation. These drugs, called bisphosphonates, include alendronate (Fosamax), etidronate (Didronel), ibandronate (Boniva), pamidronate (Aredia, generic), risedronate (Actonel), tiludronate (Skelid), and zoledronic acid (Reclast, Zometa).
Studies in 2007 and 2008 raised the possibility that people who took a bisphosphonate were more likely to develop atrial fibrillation than those who didn't take one. These findings prompted the FDA to review trials that included nearly 40,000 participants who took one of these drugs or a placebo. The review found no association between use of a bisphosphonate and atrial fibrillation.
To continue reading this article, you must log in.
Subscribe to Harvard Health Online for immediate access to health news and information from Harvard Medical School.
- Research health conditions
- Check your symptoms
- Prepare for a doctor's visit or test
- Find the best treatments and procedures for you
- Explore options for better nutrition and exercise
I'd like to receive access to Harvard Health Online for only $4.99 a month.
Sign Me UpAlready a member? Login ».
Disclaimer:
As a service to our readers, Harvard Health Publishing provides access to our library of archived content. Please note the date of last review or update on all articles.
No content on this site, regardless of date, should ever be used as a substitute for direct medical advice from your doctor or other qualified clinician.